“The aim of this study was to test the hypothesis that retinoids, such as acitretin , which bind preferentially to cellular retinoic acid binding proteins (CRABPs), or specific inhibitors of the RA hydroxylase CYP26, such as R116010, can increase the intracellular availability of ATRA.”